IDEXX Laboratories, Inc. $IDXX Stock Acquired by MGO One Seven LLC

MGO One Seven LLC increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 288.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,566 shares of the company’s stock after buying an additional 4,132 shares during the quarter. MGO One Seven LLC’s holdings in IDEXX Laboratories were worth $2,907,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of IDXX. J.Safra Asset Management Corp purchased a new stake in IDEXX Laboratories in the 2nd quarter worth about $25,000. Elevation Wealth Partners LLC grew its stake in IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after acquiring an additional 32 shares in the last quarter. Pension & Wealth Management Advisors Inc. purchased a new position in IDEXX Laboratories during the 3rd quarter valued at about $29,000. Arlington Trust Co LLC grew its stake in IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after acquiring an additional 19 shares in the last quarter. Finally, Pin Oak Investment Advisors Inc. acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at about $49,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on IDXX shares. Leerink Partners reduced their price target on shares of IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. JPMorgan Chase & Co. decreased their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a report on Friday, October 16th. Citigroup boosted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, The Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a research report on Friday, October 16th. They issued a “buy” rating and a $740.00 target price for the company. Seven analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $719.55.

Key IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Third-quarter results beat expectations: IDEXX reported adjusted earnings of $3.96 per share versus $3.71 expected, while revenue rose about 10% year over year to $1.21 billion, above estimates. Recurring diagnostics sales to veterinarians were a key growth driver. IDXX Q3 Earnings & Revenues Surpass Estimates
• Positive Sentiment: The company raised its full-year 2026 outlook, projecting EPS of $14.96–$15.16, above the $14.86 consensus, and revenue of $4.7–$4.8 billion, versus expectations of about $4.7 billion. The higher forecast reinforces optimism after the quarterly beat. IDEXX raises forecast
• Positive Sentiment: Morgan Stanley maintained an Overweight/Buy view and raised its price target to $810, signaling further potential upside in the analyst’s assessment. Morgan Stanley stock recommendations
• Positive Sentiment: A technical analysis report said IDXX moved above its 200-day moving average, a signal some investors interpret as supportive of a longer-term upward trend. IDXX crossed above the 200-day moving average
• Negative Sentiment: Analysts noted that veterinary visits remain lackluster, creating a challenging demand backdrop. IDEXX’s results were strong despite this, but the company is relying on diagnostics growth to offset softer visit trends. UBS on IDEXX’s results and vet-visit backdrop

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $672.04 on Wednesday. The firm has a market cap of $52.94 billion, a price-to-earnings ratio of 45.32 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1 year low of $500.61 and a 1 year high of $769.98. The company has a current ratio of 1.19, a quick ratio of 0.87 and a debt-to-equity ratio of 0.16. The business has a fifty day simple moving average of $538.81 and a 200 day simple moving average of $573.69.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the previous year, the company posted $3.22 earnings per share. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.79% of the stock is owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.